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P
OEMS syndrome is a rare para-neoplastic syndrome secondary to
a plasma cell dyscrasia. Effective treatment can control the disease-
related symptom complex. We describe the clinical outcome of
autologous stem cell transplantation for patients with POEMS syn-
drome, determining the impact of patient- and disease-specific factors
on prognosis. One hundred and twenty-seven patients underwent an
autologous stem cell transplantation between 1997-2010 with a median
age of 50 years (range 26-69 years). Median time from diagnosis to
autologous stem cell transplantation was 7.5 months with 32% of
patients receiving an autologous stem cell transplantation more than 12
months from diagnosis. Engraftment was seen in 97% patients and
engraftment syndrome was documented in 23% of autologous stem cell
transplantation recipients. Hematologic response was characterized as
complete response in 48.5%, partial response in 20.8%, less than partial
repsonse in 30.7%. With a median follow up of 48 months (95%CI:
38.3, 58.6), 90% of patients are alive and 16.5% of patients have pro-
gressed. The 1-year non-relapse mortality was 3.3%. The 3-year proba-
bilities of progression-free survival and overall survival are 84% and
94%, respectively, with 5-year probabilities of progression-free survival
and overall survival of 74% and 89%. In a cohort of graft recipients,
detailed organ-specific symptom response demonstrated clear symptom
benefit after autologous stem cell transplantation especially in relation
to neurological symptom control. The data analyzed in this study
demonstrate the clinical utility of autologous stem cell transplantation
for patients with POEMS syndrome. 
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Introduction 
POEMS syndrome, a rare plasma cell dyscrasia which
results in a complex of para-neoplastic clinical manifesta-
tions,1,2 is characterized by polyradiculoneuropathy,
organomegaly, multiple endocrinopathies, monoclonal pro-
tein, and dermopathy. Patients may experience sclerotic bone
lesions, extravascular fluid overload (including pleural effu-
sions and ascites), papilledema, thrombocytosis, and pul-
monary hypertension. Elevated serum levels of vascular
endothelial growth factor (VEGF), which strongly promotes
vaso-permeability, are considered to be responsible for the
characteristic symptoms of POEMS syndrome3 and can be
used for diagnostic purposes. Different angiogenic factors
such as basic fibroblast growth factor and hepatocyte growth
factor (HGF) were reported to be elevated in patients with
POEMS syndrome, suggesting that different angiogenic fac-
tors might contribute to the pathogenesis, implying a limita-
tion of clinical effect from direct VEGF blockade alone.4
Interleukin (IL)-12 has been reported to be elevated in the
serum of patients with POEMS syndrome, in association
with other pro-inflammatory cytokines such as IL-6 and
TNFα, which may have an etiological role in the pathogene-
sis of peripheral nerve demyelination.5 
The treatment of POEMS syndrome involves eliminating
the plasma cell clone, though the optimal management has
yet to be delineated, especially the role of high-dose therapy
and the use of novel biological drugs.6When compared with
patients with myeloma (MM) or light chain deposition dis-
ease, patients with POEMS syndrome have a superior overall
survival (OS). Previously published data from the Mayo
Clinic demonstrated a median OS of 13.8 years.1 The thera-
peutic management has evolved over the years, much in par-
allel with new drug developments in myeloma. In patients
with localized disease, irradiation remains the treatment of
choice.2 More recently, steroids and conventional chemother-
apy have demonstrated good disease control.7 Anti-VEGF
monoclonal antibodies may hold potential efficacy but are
associated with significant risks. Immunomodulatory drugs
(e.g. thalidomide, lenalidomide and, more recently, poma-
lidomide) are highly effective in MM, and their use in the
POEMS syndrome is evolving, though side effects can be
more pronounced, such as neuropathic effects of thalido-
mide.8-10 Dipenzieri et al. first reported the efficacy of lenalido-
mide in a patient who did not qualify for high-dose autolo-
gous stem cell transplantation (HDM/ASCT).11More recent-
ly, two studies have demonstrated promising results in the
phase II trial setting with favorable outcomes.12-14  
As with MM, the use of HDT/ASCT in patients with
POEMS has yielded encouraging results, though most report-
ed series are small and single center experiences.15-20 We,
therefore, sought to characterize the effect of ASCT as ther-
apy for patients with POEMS syndrome, determining the
effect on organ-specific dysfunction and delineating key
patient- and disease-specific factors predicting for outcome.
This multi-center retrospective analysis demonstrates the
clinical utility of ASCT when incorporated into the clinical
management of this systemic disorder.  
Methods
Patients and methods
All patients with POEMS who underwent an ASCT as part of
their first-line therapy, reported from all European Group for
Blood and Marrow Transplantation (EBMT) centers, were identi-
fied from the EBMT database as eligible for this analysis. Patient,
disease-, and transplant-related variables were collected according
to the data entries in the database based on MED A and MED B
forms, including tracking incomplete data entries from participat-
ing centers (https://www.ebmt.org/Contents/Data-Management/
Registrystructure/MED-ABdatacollectionforms/Pages/MED-AB-data-
collection-forms.aspx). Scientific and ethical review of the proposed
study was conducted by the Chronic Malignancies Working Party
(CMWP) of the EBMT, with final approval of the protocol provid-
ed by the Chair of the CMWP, ensuring that all studies were per-
formed in accordance with the principles of the Declaration of
Helsinki.
For the analysis of organ-specific disease extent and response to
transplant, a POEMS-specific questionnaire-based tool (Online
Supplementary Figure S1) was supplied to each study center  for
completion and for submission for analysis. The tool calculated
the extent of key individual organ involvement (neuropathy,
organomegaly, volume overload) pre- and post-ASCT at a point
where the treating physician considered maximum symptomatic
response had been obtained. 
Outcome measures
The response criteria of the International Myeloma Working
Group21 were modified for use in this study, with investigator-
reported response pre- and post-ASCT recorded. Complete
response (CR) was defined as: 5% or under neoplastic plasma cells
in the bone marrow (BM), and negative immunofixation of the
serum and/or urine; partial response (PR) as a 50% or over reduc-
tion in paraprotein or 90% or over reduction in urinary light chain
excretion compared with the pre-treatment baseline; stable dis-
ease (SD: <50% reduction in paraprotein with stable clinical state)
and progressive disease (PD: progressive clinical symptoms and/or
the re-appearance or progressive rise in the paraprotein level by
25% or more) were considered as treatment failure. Organ-specif-
ic symptomatic response (OR) was analyzed according to a treat-
ment-attributable change in the specific score in a time-dependent
manner.
Engraftment syndrome (ESy) was defined as previously pub-
lished.22 The definition was based on the presence of major (a tem-
perature of >38.0°C without an identifiable infectious etiology,
rash involving >25% body surface area (BSA), and non-cardio-
genic pulmonary edema) and minor [bilirubin ≥2 upper limit of
normal (ULN), transaminases ≥2 ULN, weight gain ≥2.5% of base-
line, or transient encephalopathy] criteria, with engraftment syn-
drome being defined as the presence of all 3 major criteria or one
major and 2 minor criteria within 96 hours of neutrophil engraft-
ment. 
The hematologic response rate at day (d)+100 post ASCT and
the maximum response (including time to response) was deter-
mined and compared to status at transplant. Relapse was deter-
mined as the time point associated with the onset of clinical recur-
rence or disease progression.
Statistical analysis 
Standard descriptive methods were used to report patients'
characteristics, and comparisons in subgroups were performed by
the χ2 test or Fisher Exact test (categorical variables) and Mann-
Whitney test (continuous variables). OS and progression-free sur-
vival (PFS) were computed from transplant respectively to death
(OS) or the first event between relapse/progression and death
(PFS). Probabilities of OS and PFS were calculated using the
Kaplan-Meier estimator, and differences in subgroups were
assessed by the log-rank test. Occurrence of relapse/progression
and death without this event (non-relapse mortality, NRM) were
Autologous stem cell transplantation in POEMS syndrome
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analyzed in a competing risks framework, applying the proper
non-parametric estimator of the cumulative incidence and the
Gray test for comparisons. These methods were used also to
report the achievement of complete remission (relapse/progres-
sion or death were considered competing risks) and of neutrophil
engraftment (competing with death). The graphs of time-to-event
curves report pointwise 95% confidence intervals (CI) for all prob-
abilities. Organ response (OR) was assessed comparing individual
pre- and post-transplant organ scores by the Stuart-Maxwell test
to account for dependence between the two measurements
observed for each patient. All analyses were performed using the
R package v.3.1.0 with the libraries prodlim and cmprsk (for time-
to-event end points) and irr (for organ response).
Results
Patients' characteristics and treatments
Patients’ characteristics (n=127) are illustrated in Table
1, including presenting features at diagnosis and organ
involvement. The median age at transplant was 50 years
(range 26-69 years) with a male to female ratio of 1.4:1.
87% of patients underwent an ASCT after initial dis-
ease-modifying therapy and the median time from diag-
nosis to ASCT was 7.5 months (range 0.8-346 months)
with most (69%) patients undergoing ASCT within 12
months of diagnosis. The performance score (PS) at
transplant was documented in 79% of ASCT recipients,
with 40% reporting a good PS, 29% reporting a fair PS
and 31% reporting a poor PS. Available data on baseline
and pre-ASCT albumin are limited, being available in
only 32.2% of patients at diagnosis and 39.4% at ASCT,
with a median level of 37 g/L (3-53 g/L) and 36 g/L (2-46
g/L), respectively. The availability of renal function data
is similarly limited (36.2% at diagnosis and 42.5% at
ASCT). The graft source was peripheral blood stem cells
(PBSC) in all reported ASCT with 57% of graft recipi-
ents receiving more than 4x106/kg (median CD34+ cell
dose re-infused was 4.3x106/kg). One hundred and
twenty-three (99.2%) patients were reported as receiv-
ing melphalan 200 mg/m2 as conditioning chemotherapy
and only one patient (0.8%) received total body irradia-
tion (TBI) as part of the conditioning regimen. The dis-
ease status (hematologic response) at transplant was
reported as CR/PR 48%, MR/SD 21%,  PD 18% and
untreated 13%.
G. Cook et al.
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Table 1. Patients' characteristics (P-value delineates differences between those with and without organ response data).
Total cohort Organ response Organ response  P
(n=127) not available available (χ2 test)
(n=90) (n=37)
N (%) N (%) N (%)
Sex, M/F 74/53(58%-42%) 50/40(55.6%-44.4%) 24/13 (65%-35%) 0.334
Age, yrs median (range) 49.9 (26.3, 69) 49.9 (26.8, 69) 51.8 (26.3, 69)
<40 years, n=(%) 25 (19.7%) 17 (18.9%) 8 (21.6%) 0.779
40-50 years, n=(%) 40 (31.5%) 30 (33.3%) 10 (27%)
>50 years 62 (48.8%) 43 (47.8%) 19 (51.4%)
Year of transplant
1997-1999 5 (3.9%) 4 (4.4%) 1 (2.7%)
2000-2004 42 (33.1%) 32 (35.6%) 10 (27%) 0.698
2005-2008 52 (40.9%) 36 (40%) 16 (43.3%)
>2009 (2009-2010) 28 (22%) 18 (20%) 10 (27%)
Interval diagnosis-transplant
< 1 year 87 (68.5%) 60 (66.7%) 27 (73%)
1 - 2 years 18 (14.2%) 14 (15.6%) 4 (10.8%) 0.739
≥ 2 years 22 (17.3%) 16 (17.8%) 6 (16.2%)
Organ involvement, yes/no
Peripheral neuropathy 82/0 (100%-0%) 57/0 (100%-0%) 25/0 (100%-0%)
Sclerotic bone disease 46/30 (61%-39%) 31/21 (60%-40%) 15/9 (62.5%-37.5%) 0.772
Splenomegaly 36/44 (45%-55%) 26/30 (46.4%-53.6%) 10/14 (41.7%-58.3%) 0.695
Hepatomegaly 37/43(46.2%-53.8%) 27/29 (48.2%-51.8%) 10/14 (41.7%-58.3%) 0.590
Lymphadenopathy 26/54 (32.5%-67.5%) 18/38 (32.1-67.9%) 8/16 (33.3%-66.7%) 0.917
Dermopathy 60/14 (81%-19%) 44/6 (88%-12%) 16/8 (67%-33%) 0.061
Endocrinopathy 56/23 (71%-29%) 38/17 (69%-31%) 18/6 (75%-25%) 0.863
Papilledema 29/39 (43%-57%) 21/27 (43.8%-56.2%) 8/12 (40%-60%) 0.914
Disease status at ASCT*
Untreated 13 (12.6%) 7 (9%) 6 (24%)
CR 6 (5.8%) 5 (6.4%) 1 (4%)
PR 43 (41.7%) 35 (44.9%) 8 (32%) 0.364
MR 5 (4.9%) 3 (3.9%) 2 (8%)
SD 17 (16.5%) 14 (17.9%) 3 (12%)
PD 19 (18.4%) 14 (17.9%) 5 (20%)
Missing 24 (18.9%) 12 (13.3%) 12 (32.4%)
OR: organ response; M: male; F: female; ASCT: autologous stem cell transplantation; CR: complete response; PR: partial response; SD: stable disease; MR: <PR and more than SD;
PD: progressive clinical symptoms and/or the re-appearance or progressive rise in the paraprotein level by ≥25%) *Investigator-reported response.
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Transplant results: engraftment and engraftment 
syndrome
Successful engraftment was documented in 96.8%
(n=123) with engraftment failure reported in 3 patients (2
patients with primary graft failure and one with secondary
graft failure; one patient with missing data). The median
time to neutrophil engraftment was 13 days and the medi-
an time to platelet engraftment was 16 days. The esti-
mates of cumulative incidence of neutrophil engraftment
are illustrated in Online Supplementary Figure S1A.
Engraftment syndrome was reported in 29 patients (23%),
manifested by a heterogeneous clinical presentation
(Figure 1) and treated with a high dose of corticosteroids.
There was no difference in the incidence of engraftment
syndrome based on previous treatment, reported in 24%
of pre-treated versus 46% untreated patients pre ASCT
(P=0.178), nor  did we determine any impact on PBSC
mobilization regardless of whether this was conducted
with or without cyclophosphamide (cyclophosphamide-
based mobilization ESy rate of 26.9% compared with
non-cyclophosphamide-based mobilization ESy rate of
25.9%; Fisher Exact test P=0.590), though these results
must be interpreted with caution  due to the  limited data
availability on the mobilization regimens used. We
observed no obvious negative impact on survival in
patients who did or did not experience engraftment syn-
drome: 5-year OS was 90% (95%CI: 79-100) for no ESy
compared with 97% (95%CI: 90-100; P=0.7).
Organ-specific responses and durability of response
The hematologic response (HR) in evaluable patients
(n=101) post ASCT was  CRHR in 49 patients (48%) with
a median time to CRHR of 4.6 months (Figure 2A), PRHR in
21 patients (21%), less than PRHR in 31 patients (31%).
Sixteen patients up-graded their response to CRHR fol-
lowing ASCT, with 9 patients up-grading their response to
PRHR following ASCT. Using the clinical scoring tool
(Online Supplementary Figure S2), the organ-specific
responses pre- and post-ASCT were determined; no differ-
ence in PFS was seen between the cohort with and that
without OR information (Online Supplementary Figure S2).
Organ symptom response was variable across the
domains. For example, in the neurological symptom
domain, where all patients experienced at least one symp-
tom complex, 7 (16%) patients had resolution of pain, 7
(17%) had resolution of paraesthesia, and 8 (19%) had res-
olution of mobility limitations with 4 (11%) patients
resolving balance issues (Figure 2B). In the cohort with
reported organ-specific response (n=37), the majority of
patients reported an improvement in their symptoms post
ASCT, with patients achieving a symptomatic CR with
prior therapy maintaining this in the post-ASCT follow-up
period (Figure 2C). 
At last follow up, 21 (17%) patients demonstrated pro-
gressive disease. The 3-year relapse rate (RR) for the
cohort was 12% (95%CI: 5, 18%) (Figure 3A). Median PFS
for the cohort was 106 months [95% CI: 87.8, not reached
(NR)] with a 5-year PFS of 74% (95%CI: 63.2, 83.7%)
(Figure 3B).  Median PFS for patients in whom OR data
were available was 88 months (95%CI: 51, NR) with a 5-
year PFS of 67% (95%CI: 45.7, 88.7) (Figure 3C). In a uni-
variate analysis, the only factor to demonstrate signifi-
cance in relation to PFS was PS: patients with a good score
(0-1: median PFS NR, 95%CI: 92, NR) compared to those
with fair (2: median 77 months 95%CI: 14, NR) and poor
(≥3: median 89 months 95%CI: 57, NR) scores (log-rank
P=0.032) (Online Supplementary Figure S3). No impact on
PFS was noted either from the time to transplant (<1 year,
1-2 years or >2 years),  use of pre-transplant therapy, or
the status at transplant (CR vs. <CR).
Survival
A total of 114 (90%) patients are alive at last follow up
with a median follow up of 48 months (95%CI: 38.3,
58.6). Thirteen patients have died, of whom 4 (31%)
resulted from disease progression, 3 (23%) died from
infection, with 6 patients dying from other causes. There
were 3 reported incidences of secondary primary malig-
nancy (2.9%; data missing in 9 patients): one patient was
diagnosed with myelodysplastic syndrome (MDS), one
patient with myelodysplasia, and one patient with col-
orectal carcinoma. NRM rates at d+30 and d+100 were
1.6% (95%CI: 0, 3.8) and 2.4% (95%CI: 0, 5.0). The 
1- and 5-year NRM were 3.3% (95%CI: 0.1, 6.4) and 7.7%
(95%CI: 1.9, 13.6), respectively (Figure 4). The 5-year OS
for the cohort was 88.6% (95%CI: 81.5, 95.8%) (Figure 5).
No impact on OS was seen either on the time to transplant
(<1 year, 1-2 years or >2 years),   use of pre-transplant ther-
apy, or  status at transplant (CR vs. <CR).
Discussion 
Autologous stem cell transplantation has become stan-
dard first-line therapy in patients with plasma cell dyscra-
sia, and has been reported to be a suitable treatment
modality in POEMS syndrome.17,20,23  Although a recently
reported non-ASCT treatment modality has shown good
disease control, the long-term outcome from ASCT in
POEMS syndrome has been shown to be extremely good.7
D’Souza et al. reported the results from long-term follow
up, categorized according to responses seen in hematolog-
ic, radiological, biochemical (VEGF) and clinical parame-
ters.16 Given that the clinical phenotype relates to organ-
specific symptomatology, a clinical correlation with the
hematologic response post ASCT is warranted. The
Autologous stem cell transplantation in POEMS syndrome
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Figure 1. The clinical presentation of engraftment syndrome (ESy) in POEMS
syndrome patients undergoing autologous stem cell transplantation (ASCT)
(n=29). 
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results presented in this study demonstrate that ASCT in
POEMS syndrome not only results in excellent hematolog-
ic control, but also excellent organ-specific disease
response.  
This present study  defines several key clinical issues.
Firstly,  data regarding POEMS syndrome patients under-
going ASCT are limited, though many case reports pro-
vide information on  individual responses. In this, the
largest multi-center cohort reported so far, we demon-
strate that ASCT has a clear impact  both in terms of PFS
and OS, with good cohort follow up and completion of
data. D’Souza et al.16 report a single center experience with
G. Cook et al.
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Figure 2. Response to autologous stem cell transplantation (ASCT) in patients with POEMS syndrome. (A) Cumulative incidence of complete hematologic response
(CHR) post ASCT. (B) Individual symptomatic domain score modification pre- and post-ASCT, where the Y-axis represents the absolute number of patients (n).
Comparative analysis was performed using the Stuart-Maxwell test to determine statistically significant differences on comparative groups of outcomes. (C) Domain-
specific response grading post-ASCT, where the Y-axis represents the absolute number of patients (n).  CR: complete response; “Keeps CR”: no symptoms pre- and
remain asymptomatic post ASCT; “No change”: mild, moderate and severe before ASCT remain in a similar category post ASCT. 
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excellent follow up, clearly showing the impact of ASCT,
with results similar to those  presented here. The median
overall survival of our cohort has not been reached, which,
given the follow-up period, is indicative of the durability
of responses in this rare syndrome. 
Secondly,  delivery of a therapy which can have  such a
positive impact must not carry  with it an unacceptable
risk. Our data demonstrate procedural safety with a 
1-year NRM of 3.3%, which is somewhat surprising given
the extent to which this therapy can compromise patients'
physiological status.  In particular, the pro-inflammatory
Esy (manifested by fever, weight gain, pulmonary infil-
trates, rashes and diarrhea) was reported in 23% of
patients, compared to the previously reported 37%.16 It
has been suggested that  incidence of Esy can be reduced
if patients have peripheral blood stem cell mobilization
incorporating cyclophosphamide, perhaps relating to the
immune-modulatory capacity of high-dose cyclophos-
phamide. The incidence of ESy in ASCT performed for
myeloma patients has seen an increase in association with
the introduction of novel agents.24 In the current era of bio-
logical disease-modifying agents and pre-transplant treat-
ment strategies, this remains an issue worthy of explo-
ration. 
Thirdly, given the systemic manifestations of POEMS
syndrome, there is a need to encompass the systemic
nature of the disorder when defining effective therapies
rather than reliance on laboratory parameters of response
alone. Until now, reported data factoring objective organ
response have been particularly limited and no uniform
scoring system or patient-reported outcome (PRO) tool
has been applied. In this study cohort, we used an objec-
tive organ-specific symptom PRO to gain insight into the
systemic response to ASCT. Though not a linearized scale,
this PRO tool has been able to demonstrate the impact of
ASCT on the propagation of systemic symptoms with
complete resolution in specific symptoms in 10%-20% of
patients but with a general improvement in symptomatic
scoring being reported in the majority of patients.  What is
interesting to note is the relative lack of a connection
between objective symptomatic response and laboratory-
based response. As  previously reported, this observation
continues to be valid even in this larger series of patients.
It is important to note that patients who do not achieve or
who fail to remain in CR, are those patients most at risk
of systematic relapse disease.25 It would be very useful to
further define PRO tools in this setting, especially in rela-
tion to pre-ASCT therapy.
It is important to review the data presented in this man-
uscript in the  light of the limitations of the study. Firstly,
the hematologic response post ASCT (Figure 2A) seems to
indicate a continuing CR evolution up to 24-72 months
post ASCT. There is no recorded post ASCT therapy with-
in the data fields, so further consideration of this phenom-
enon is warranted.  A delayed response has been observed
Autologous stem cell transplantation in POEMS syndrome
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Figure 3. (A) Cumulative rate of disease progression and (B) progression-free
survival (PFS) of patients with POEMS syndrome undergoing an autologous stem
cell transplantation (ASCT). (C) PFS in sub-group assessed for organ response.
Shaded area represents 95% confidence intervals.
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in other monoclonal gammopathies, e.g. in AL amyloido-
sis27 and Waldenstrom macroglobulinemia.28 Alternatively,
from a  statistical perspective, the estimated CR rate and
its increase in time should be interpreted with caution
given the enlarging confidence intervals with each advanc-
ing time frame. The observed phenomenon in this study
may well reflect both these explanations as a cumulative
effect. 
Secondly, due to the retrospective nature of the work, as
well as the contribution from many international centers,
there was no routine monitoring of VEGF serum level  or
any  consistent reporting of newer imaging techniques
(e.g. PET/CT scanning). Furthermore,  in this transplant
registry database, full recording of comorbidities is limited
and therefore we were  not able to include this in the
analysis. The organ-specific response data, whilst very
informative on a clinical basis, does represent a sub-group
analysis, which is a limitation of the retrospective nature
of the study. None the less, the comprehensive analysis of
the largest ASCT cohort in POEMS patients does provide
key clinical conclusions to aid the physician. 
We show the long-term outcomes of patients with
POEMS syndrome treated with ASCT, with a sub-group
analysis showing the impact of the treatment on the sys-
temic manifestations of this syndrome. Patients can
progress/relapse after transplantation, and therefore should
be followed periodically. Given the paucity of post-ASCT
events, performing univariate and multivariate analysis to
establish independent factors of predicting OS remains the
main limitation. The analysis to identify risk factors for pro-
gression post transplant demonstrated that the PS at time of
transplant is the most significant. The use of appropriate
pre-transplant therapy to control disease-related symptoms,
and thus PS, at the time of transplant warrants further con-
sideration. Though this study is retrospective, given the rel-
ative rarity of this syndrome, the data presented are key to
the clinician's decision-making process. 
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